Several case-control studies associated low circulating levels of adiponectin with an increased breast cancer risk and the development of a more aggressive phenotype in post-menopausal women, regardless of BMI, leptin, and IGF-I levels (85–92). Here, ADIPOQ is linked to breast cancer.